IL6 and synovial sarcoma: Moreover, considering the shared inflammatory pathways, such as IFN-I signaling, IL-6, and endothelial dysfunction, between SS and AS, targeted immunotherapy may not only control systemic inflammation and glandular damage but also delay atherosclerotic progression, offering a more comprehensive therapeutic strategy for patients with systemic autoimmune diseases [13,28].